Optimising malignant melanoma management in Europe
EUMelaReg collects health information to improve care and treatment for patients with skin cancer
Sustaining and fostering collaboration between academia and industry
for the collection of baseline, treatment and outcome data of representative samples of malignant melanoma patients of major European countries.
Building the largest and quickest melanoma registry in the world
EUMelaReg collects real-world data on melanoma patients throughout Europe and integrates them in a data warehouse.

EUMelaReg PD-SEQ poster presented at SMR congress 2023

An EUMelaReg real world evidence study with the title “Upfront usage of single agent anti-PD1 antibodies versus combined BRAF and MEK inhibitors in metastatic or unresectable BRAF V600 mutated melanoma” was accepted as poster presentation at the 20th SMR congress in Philadelphia, USA. Examined with EUMelaReg data, the study analysed patients with metastatic or nonresectable BRAF V600 mutated melanoma, who received either BRAF/MEKi combination, or single agent anti-PD1 antibody treatment in the first line setting. The aim of this study was to understand the clinical characteristics associated with treatment allocation in first line unresectable or metastatic BRAF V600 mutated melanoma besides combined ICI with Ipi/Nivo in order to evaluate which treatment choice could be paramount for patient's ineligible for Ipi/Nivo.